Cardiovascular and kidney outcomes of semaglutide and the annual eGFR slope in adults with and without type 2 diabetes: data extraction sheet, analysis code and search records for a systematic review and meta-analysis of randomised controlled trials

Supporting materials for a systematic review and meta-analysis of randomised, placebo-controlled trials of semaglutide in adults with and without type 2 diabetes (PROSPERO CRD420261496524). Contents:(1) the standardised data extraction sheet used to record trial characteristics, risk-of-bias judgements and outcome data for the seven included trials;(2) the analysis code used to reproduce all pooled effect estimates — hazard ratios for MACE-3, the kidney composite endpoint, heart-failure hospitalisation/events, and all-cause and cardiovascular death, and the mean difference for the annual eGFR slope — together with heterogeneity statistics, prediction intervals, prespecified subgroup and sensitivity analyses, publication-bias tests and trial sequential analysis;(3) the complete search strategies and search records for PubMed/MEDLINE, Embase, CENTRAL, ClinicalTrials.gov and the WHO ICTRP, including the deduplicated record set; and (4) the figure-generation code for all main and supplementary figures. The code also performs the analyses added during revision: restricted maximum likelihood estimation of tau-squared alongside the primary maximum likelihood estimates, a k = 4 eGFR-slope sensitivity analysis in which the two estimates taken from the same post hoc analysis enter as a single input, leave-one-out analysis of the kidney composite endpoint, and absolute effects (events avoided per 1000 participants and numbers needed to treat). No copyrighted full texts of the included publications are included, and no individual participant data were used: all analyses are based on published trial-level summary statistics.